Aromatase Inhibitors–Past, Present and Future
2005
Role of Aromatase Inhibitors in Breast Cancer
publication
Evidence: high
Author Information
Author(s): Carpenter R, Miller W R
Primary Institution: The Breast & Endocrine Unit, St Bartholomew's Hospital, London; Edinburgh Breast Unit Research Group, University of Edinburgh
Conclusion
Aromatase inhibitors are becoming a valuable addition to breast cancer therapy for postmenopausal women with estrogen receptor-positive tumors.
Supporting Evidence
- Aromatase inhibitors have shown improved disease-free survival compared to tamoxifen in several trials.
- Letrozole has been shown to be more effective than tamoxifen in the neoadjuvant setting.
- Exemestane has demonstrated a favorable safety profile compared to tamoxifen.
Takeaway
Aromatase inhibitors help treat breast cancer by lowering estrogen levels, which many breast cancers need to grow.
Methodology
The paper reviews the role of aromatase inhibitors in breast cancer treatment, focusing on their efficacy and safety profiles compared to tamoxifen.
Participant Demographics
Primarily postmenopausal women with breast cancer.
Statistical Information
P-Value
P=0.04
Confidence Interval
95% CI=0.42–0.82
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website